Sugi Predict

Sugi Predict / Compounds / SCHEMBL30135255

SCHEMBL30135255

SCHEMBL30135255

CC(C)S(=O)(=O)N1CCCNCCCNCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.42
▸ EPHX2 P34913 1/20 0.38
▸ TP53 P04637 2/20 0.33
▸ CYP1A2 P05177 2/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ CYP2D6 P10635 2/20 0.33
▸ NFKB1 P19838 2/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ MYLK Q15746 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ GMNN O75496 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ ROCK1 Q13464 2/20 0.33
▸ TSHR P16473 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ MTOR P42345 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15893901 0.94 KDM4E (0.50) KDM4EEPHX2TP53CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL2595097 0.92 KDM4E (0.48) KDM4EEPHX2TP53CYP1A2CYP3A4
SCHEMBL4376376 0.85 KDM4E (0.46) KDM4EEPHX2CYP3A4KMT2AMAPT
SCHEMBL190916 0.85 KDM4E (0.46) KDM4EEPHX2CYP3A4KMT2AMAPT
Hydrochloric Acid SCHEMBL2249026 0.83 KDM4E (0.45) KDM4EEPHX2MAPK1KMT2AGMNN
SCHEMBL5405216 0.82 EPHX2 (0.44) KDM4EEPHX2CYP3A4MEN1KMT2A
SCHEMBL16022965 0.82 EPHX2 (0.44) EPHX2CYP3A4MEN1KMT2ALMNA
SCHEMBL24735804 0.80 CA1 (0.48) KDM4EEPHX2CYP3A4MEN1KMT2A
SCHEMBL15893903 0.80 CA1 (0.48) KDM4EEPHX2CYP3A4MEN1KMT2A
SCHEMBL777414 0.80 CA1 (0.48) KDM4EEPHX2CYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors KEZAR LIFE SCIENCES, INC. (US) 2026-04-14 — — US disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 — — US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G KDM4E 4672/4885EPHX2 2484/4885TP53 1481/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G KDM4E 4689/4885EPHX2 2364/4885TP53 1470/4885
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors CD274, CD40, ICOS KDM4E 2225/4885EPHX2 4070/4885TP53 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.